drugset / Trial / NCT04086823
A Single Blind, Randomized, Placebo-controlled, Phase 2a, 2-cohort Study for the Evaluation of Safety and Efficacy of RZL-012 for Submental Fat Reduction in Healthy Volunteers.
RandomizedParallel-groupSingle-blindTreatment
Summary
Twenty-Eight (28) subjects (12 for cohort 1 and 16 for cohort 2 ) will be included in the study. Subjects in each cohort will be injected with a different dose of RZL-012. The total of 28 subjects will be enrolled in 2 clinical sites.
Timeline
- Start
- 2020-02-25
- Primary completion
- 2020-09-16
- Completion
- 2020-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | UTENPANIUM | Small molecule | 120 mg | Subcutaneous |
| Comparator | UTENPANIUM | Small molecule | 240 mg | Subcutaneous |
Indications
No indication recorded.